Skip to main content

Acumen Pharmaceuticals Inc (ABOS) Stock

Acumen Pharmaceuticals Inc Stock Details, Movements and Public Alerts

Stock Details

Acumen Pharmaceuticals Inc (ABOS), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $3.29. Over the past 52 weeks, it has ranged between $0.86 and $3.60. This places the current price at 91.4% of its 52-week high and 284.8% above its 52-week low. Recent trading volume was recorded at 1,260. The 14-day Relative Strength Index (RSI) stands at 66.23, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $2.53 by 30.04%. Similarly, it is above its 200-day moving average of $1.84 by 78.80%. The MACD histogram is 0.00, indicating neutral momentum (MACD Line: 0.24, Signal Line: 0.24). There is currently 1 active alert set for ABOS by users.

52-Week Range

$3.60 - $0.86

-8.61% from high · +284.80% from low

Avg Daily Volume

763,297

20-day average

100-day avg: 548,614

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

2.13

EV/EBITDA

-0.60

EPS (TTM)

-$2.21

Price to Sales

538.78

Beta

0.21

Less volatile than market

Q:How is ABOS valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is ABOS's risk profile compared to the market?
With a beta of 0.21, Acumen Pharmaceuticals Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 2.13 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-138,170,000

Return on Equity

-85.90%

Return on Assets

-42.20%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is ABOS's business model?
Profitability metrics are not available for this stock.
Q:What are ABOS's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$198.1M

Revenue (TTM)

$329,000

Revenue/Share (TTM)

$0.03

Shares Outstanding

60.57M

Book Value/Share

$1.54

Asset Type

Common Stock

Q:What is ABOS's market capitalization and position?
Acumen Pharmaceuticals Inc has a market capitalization of $198.1M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 60.57M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does ABOS's price compare to its book value?
Acumen Pharmaceuticals Inc's book value per share is $1.54, while the current stock price is $3.29, resulting in a price-to-book (P/B) ratio of 2.14. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$7.00

112.77% upside potential

Analyst Recommendations

Strong Buy

0

Buy

6

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for ABOS?
6 analysts cover ABOS with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $7.00 implies 112.8% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ABOS?
Current analyst recommendations:06 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 17, 2026, 02:18 AM

Technical Indicators

RSI (14-day)

66.23

Neutral

50-Day Moving Average

$2.53

30.04% above MA-50

200-Day Moving Average

$1.84

78.80% above MA-200

MACD Line

0.24

MACD Signal

0.24

MACD Histogram

N/A

Neutral

Q:What does ABOS's RSI value tell investors?
The RSI (Relative Strength Index) for ABOS is currently 66.23, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret ABOS's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.24 below the signal line at 0.24, with histogram at 0.00. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($2.53) is above the 200-day MA ($1.84), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Mar 17, 2026, 12:48 AM

Active Alerts

Alert Condition
Golden Cross
Threshold
N/A
Created
Jan 26, 2026, 10:19 AM

Stay Ahead of the Market with Acumen Pharmaceuticals Inc Alerts

Set up price alerts for Acumen Pharmaceuticals Inc and get notified instantly when the price hits your target. Never miss an important price movement again.